Pancreatic Ductal Adenocarcinoma (PDAC)
Conditions
Keywords
Pancreatic ductal adenocarcinoma, Ribosomal protein SA (RPSA), prognosis biomarker
Brief summary
PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of PDAC remains poor at this time. Its management is based on surgery for early stages, associated with neoadjuvant and adjuvant chemotherapy. However, around 80% of patients will relapse after surgery. There is a lack of efficient biological biomarkers of PDAC, especially for prognosis. To date, CA19-9 is commonly used despite its lack of sensitivity and specificity. Ribosomal protein SA (RPSA) is a transmembrane receptor localized at the cell surface but also in the cytosolic and nuclear regions. RPSA interacts with many proteins in the extracellular matrix (ECM), including laminin-1 and elastin. RPSA in involved in different cellular functions such as cell adhesion, migration, proliferation and differentiation. The expression of RPSA is increased in many cancers including breast, lung, prostate, pancreatic, etc. It could represent a molecular biomarker of tumor invasion and metastatic abilities. Moreover, the concentration of RPSA could be measured in the serum of patients with PDAC. Recent data suggest that a modification of the RPSA concentration could be a prognostic biomarker of PDAC.
Detailed description
The aim of this study is to explore the potential implication of RPSA as prognostic biomarker of PDAC.
Interventions
OTHERBlood sample
Blood sample
Sponsors
CHU de Reims
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: * Patients treated at the Reims University Hospital for a resectable or potentially resectable pancreatic tumor, with or without neoadjuvant chemotherapy * Adults (aged more than 18 years old) * Patients who have signed the informed consent form
Exclusion criteria
: * Patients with a prior history of cancer (excluding basal cell carcinoma or in situ cervical cancer that received conventional cancer treatment). * Minors * Patients for whom PDAC is not the retained diagnosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| RPSA serum concentration | Day 0 | The RPSA serum concentration is assessed with commercially available RPSA ELISA assay (MyBioSource - MBS9137288). |
Countries
France
Contacts
Primary ContactJean-Baptiste OUDART
Outcome results
None listed